INT199510

From wiki-pain
Revision as of 09:56, 22 September 2012 by Daniel (Talk | contribs)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Context Info
Confidence 0.47
First Reported 2005
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 15
Total Number 15
Disease Relevance 20.99
Pain Relevance 1.12

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Golgi apparatus (STIP1) nucleus (STIP1) protein complex (STIP1)
response to stress (STIP1) cytoplasm (STIP1)
Anatomy Link Frequency
stigma 1
STIP1 (Homo sapiens)
Pain Link Frequency Relevance Heat
Duloxetine 212 99.38 Very High Very High Very High
Eae 16 85.16 High High
Pain 32 83.12 Quite High
monoamine 8 57.84 Quite High
headache 4 24.80 Low Low
Inflammation 25 12.88 Low Low
Spinal cord 16 5.00 Very Low Very Low Very Low
Serotonin 16 5.00 Very Low Very Low Very Low
depression 16 5.00 Very Low Very Low Very Low
Neurotransmitter 16 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Infection 1382 100.00 Very High Very High Very High
Acquired Immune Deficiency Syndrome Or Hiv Infection 631 99.96 Very High Very High Very High
Trepenoma Infection 585 98.76 Very High Very High Very High
Congenital Syphilis 136 97.72 Very High Very High Very High
Incontinence 40 97.28 Very High Very High Very High
Stress Incontinence 164 96.68 Very High Very High Very High
Gonorrhea 482 96.24 Very High Very High Very High
Chlamydia Infection 748 95.80 Very High Very High Very High
Confusion 4 88.40 High High
Peripheral Arterial Disease 8 87.40 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
That is, in terms of preventing STI-attributable HIV cases, we assumed that treating an STI provided only one-fourth the potential benefit of preventing the STI altogether.
Negative_regulation (preventing) of STI associated with acquired immune deficiency syndrome or hiv infection and infection
1) Confidence 0.47 Published 2008 Journal Cost Eff Resour Alloc Section Body Doc Link PMC2426671 Disease Relevance 2.73 Pain Relevance 0
The formulas for estimating the reduction in STI-attributable HIV infections and for estimating the number of HIV infections averted by HIV counseling and testing are based on simple models, and may be more applicable for certain areas than others depending on factors such as HIV prevalence and HIV co-infection in people with STIs.
Negative_regulation (reduction) of STI-attributable associated with acquired immune deficiency syndrome or hiv infection and infection
2) Confidence 0.47 Published 2008 Journal Cost Eff Resour Alloc Section Body Doc Link PMC2426671 Disease Relevance 2.67 Pain Relevance 0
Previous studies, too, suggest that young adults can feel uncomfortable informing their sexual partners about a positive diagnosis of an STI [15,28].
Negative_regulation (diagnosis) of an STI
3) Confidence 0.37 Published 2010 Journal BMC Res Notes Section Body Doc Link PMC2930645 Disease Relevance 0.05 Pain Relevance 0
First, our estimates of the costs averted by preventing a given STI may be overstated relative to the costs averted by preventing another STI.
Negative_regulation (preventing) of STI associated with infection
4) Confidence 0.35 Published 2008 Journal Cost Eff Resour Alloc Section Body Doc Link PMC2426671 Disease Relevance 2.08 Pain Relevance 0.08
These benefits included the sequelae costs averted by treatment of people with STIs, the prevention of congenital syphilis in infants born to mothers treated for P&S syphilis, the interruption of STI transmission in the population, the reduction in STI-attributable HIV infections (HIV infections that would not have occurred without the facilitative effects of STIs on HIV transmission and acquisition), HIV infections averted by HIV counseling and testing, and the corresponding reductions in lost productivity.
Negative_regulation (reduction) of STI-attributable associated with acquired immune deficiency syndrome or hiv infection, trepenoma infection, congenital syphilis and infection
5) Confidence 0.35 Published 2008 Journal Cost Eff Resour Alloc Section Body Doc Link PMC2426671 Disease Relevance 2.04 Pain Relevance 0
First, our estimates of the costs averted by preventing a given STI may be overstated relative to the costs averted by preventing another STI.
Negative_regulation (preventing) of STI associated with infection
6) Confidence 0.35 Published 2008 Journal Cost Eff Resour Alloc Section Body Doc Link PMC2426671 Disease Relevance 1.92 Pain Relevance 0.08
We used Monte Carlo simulations [87] to generate a range of the most plausible estimates of the costs averted by STI prevention.
Negative_regulation (prevention) of STI associated with infection
7) Confidence 0.35 Published 2008 Journal Cost Eff Resour Alloc Section Body Doc Link PMC2426671 Disease Relevance 1.22 Pain Relevance 0
That is, in terms of preventing STI-attributable HIV cases, we assumed that treating an STI provided only one-fourth the potential benefit of preventing the STI altogether.
Negative_regulation (preventing) of STI-attributable associated with acquired immune deficiency syndrome or hiv infection and infection
8) Confidence 0.35 Published 2008 Journal Cost Eff Resour Alloc Section Body Doc Link PMC2426671 Disease Relevance 2.85 Pain Relevance 0
In developing the formula for costs averted by preventing STI-attributable HIV infections, we excluded people treated for STIs as a result of partner notification, to reduce potential double-counting of the benefits of preventing STI-attributable HIV infections in partners of infected people treated for STIs.
Negative_regulation (preventing) of STI-attributable associated with acquired immune deficiency syndrome or hiv infection and infection
9) Confidence 0.35 Published 2008 Journal Cost Eff Resour Alloc Section Body Doc Link PMC2426671 Disease Relevance 2.40 Pain Relevance 0
The MSM we interviewed gave almost no indication that there had been any type of dialogue regarding STI prevention during their visit.
Negative_regulation (prevention) of STI
10) Confidence 0.26 Published 2007 Journal BMC Public Health Section Body Doc Link PMC1797160 Disease Relevance 0.66 Pain Relevance 0
In conclusion, the major themes that emerged from participant narratives included the importance of low STI-related knowledge and high perceived stigma, both in terms of STIs as well as other types of social stigma, on STI care-seeking delays.
Negative_regulation (delays) of STI in stigma associated with infection
11) Confidence 0.26 Published 2007 Journal BMC Public Health Section Body Doc Link PMC1797160 Disease Relevance 0.16 Pain Relevance 0
In all four studies, women treated with duloxetine demonstrated a 50%–58% median decrease in IEF compared to 27%–40% seen with placebo (Norton et al 2002; Dmochowski et al 2003; Millard et al 2004; van Kerrebroeck et al 2004).
Negative_regulation (decrease) of IEF associated with duloxetine
12) Confidence 0.00 Published 2005 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC1661641 Disease Relevance 0.55 Pain Relevance 0.27
The efficacy was evaluated based on the reduction of the IEF, which was collected with patient diaries and with the aid of the I-QOL and PGI-I questionnaires that evaluated quality of life.
Negative_regulation (reduction) of IEF
13) Confidence 0.00 Published 2005 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC1661641 Disease Relevance 0.75 Pain Relevance 0.11
The last-visit analysis showed a significant but not dose-dependent reduction in IEF.
Negative_regulation (reduction) of IEF
14) Confidence 0.00 Published 2005 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC1661641 Disease Relevance 0.42 Pain Relevance 0.18
Both duloxetine alone and duloxetine in combination with PFMT significantly (p < 0.05) reduced the median IEF by 57%, compared with 35% reduction with PFMT alone (29% reduction with no treatment) (Ghoniem et al 2005).
Negative_regulation (reduced) of IEF associated with duloxetine
15) Confidence 0.00 Published 2005 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC1661641 Disease Relevance 0.48 Pain Relevance 0.40

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox